Navigation Links
Tay-Sachs Disease Stem Cell Gene Enzyme Treatment
Date:11/10/2010

SARASOTA, Fla., Nov. 10, 2010 /PRNewswire/ -- StemCellRegenMed, Inc. announces that a new stem cell gene and enzyme replacement treatment has been performed on a fourteen month old child with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a devastating disease that afflicts children primarily of parents of Jewish heritage and in very rare cases families of Eastern European background and the Cajun region in the U.S.A. The children appear normal at birth but about six months of age they lose their ability to turn over both ways; raise their heads or crawl. They become hypotonic and even have difficulty in swallowing and sucking. Between 15-18 months they may become blind and lose their hearing. Death may occur by two years of age.

The procedure was performed at a major hospital in Lima, Peru under the supervision of Burton Feinerman, M.D. trained at the Mayo Clinic in Rochester, MN and Javier Paino, M.D., Ph.D neurosurgeon and scientist trained at Mt. Sinai Hospital, N.Y. and George Washington University School of Medicine.

The therapy consisted of administration of neuron stem cells mixed with brain derived neurotrophic factor, glial derived neurotrophic factor, nerve growth factor into the central nervous system via the spinal canal to the brain and spinal cord. This procedure was repeated again in two days.

Following this an agent was started orally and given twice daily to increase the levels of an enzyme B-hexosaminidase A. This enzyme is absent or very low in patients with Tay-Sachs leading to a defect in glycolysis that results in an abnormal accumulation of fatty substances in the brain and spinal cord causing damage to the nervous system, hearing and visual centers.

The baby, Aspen Brown, has tolerated all aspects of the treatment well.  Both parents have noted movement of the head and neck that had been completely restricted; the child follows moving objects; muscle tone has improved; grasp reflex seems better all of which occurred in two to four days after treatment. Plans are now being developed to introduce the Hexa A gene with a vector or possibly work with developing a induced silenced complex RNA.

For further information contact Burton Feinerman, M.D. at 1-888-620-0411 or (941)388-2277.  E-mail contact at info@stemcellregenmed.com or bfeinerman@hotmail.com


'/>"/>
SOURCE StemCellRegenMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinsons Disease
2. Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now Available at ReportsandReports
3. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
4. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
5. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
6. 550 People Across Europe Will Die Today From a Preventable Lung Disease
7. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
8. Major disease-vector mosquito reveals the secrets of its immune system
9. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
10. Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimers disease
11. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  PTC Therapeutics, Inc. (NASDAQ: ... (Strategies to Realize Innovation, Vision and Empowerment) grant ... provides funds to patient advocacy organizations to develop ... contributions to the rare disease community by increasing ... patient advocates. Mary Frances Harmon ...
(Date:2/11/2016)... Feb. 11, 2016  Vermillion, Inc. (NASDAQ: VRML ... today announced the formation of the Steering Committee for ... --> Pelvic masses can present physicians ... management. Once pregnancy is ruled out, pelvic masses may ... advanced endometriosis, benign ovarian tumors and gastrointestinal and urinary ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today ... Portland, Oregon -based community care ... provide population health analytics, quality reporting and care ... FamilyCare strengthen its team of quality managers, analysts ... to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... BioInformant announces the February 2016 release of its ... and Technologies – Market Size, Segments, Trends, and Projections ... The first and only market research firm ... more than a decade of historical information on all ... type. This powerful 175 page global strategic report contains ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
Breaking Biology News(10 mins):